First experiences in real clinical practice treating a patient with generalised pustular psoriasis with Spesolimab

Abstract

AbstractGeneralised pustular psoriasis is a rare, unpredictable, and sometimes severe subtype of psoriasis whose treatment is hampered by a lack of consensus and standardised therapeutic guidelines. The recent recognition of the involvement of the innate interleukin (IL)‐1/IL‐36 pathway has allowed the development of new biologic drugs such as Spesolimab. We present the case of a woman with persistent generalised pustular psoriasis (GGP) who, after numerous failures with several systemic and biologic therapies, was treated with Spesolimab and showed a very rapid and sustained response over time.